Anzeige
Mehr »
Montag, 06.10.2025 - Börsentäglich über 12.000 News
Das Paradox-Becken beweist seine Stärke - und American Critical Minerals sitzt direkt darauf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A414BN | ISIN: US47010C8881 | Ticker-Symbol: 1JA0
NASDAQ
06.10.25 | 18:43
2,180 US-Dollar
-1,58 % -0,035
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
JAGUAR HEALTH INC Chart 1 Jahr
5-Tage-Chart
JAGUAR HEALTH INC 5-Tage-Chart

Aktuelle News zur JAGUAR HEALTH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15:18Jaguar Health reports positive results in MVID treatment trial3
15:02Jaguar Health, Inc.: Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease94Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support (PS) (comprised of total parenteral...
► Artikel lesen
FrJaguar Health registers 2.62M shares for resale following private placements2
JAGUAR HEALTH Aktie jetzt für 0€ handeln
MiJaguar Health, Inc. - 8-K, Current Report10
DiJaguar Health stellt Strategie für Crofelemer vor: Neue Indikationen und Partnerschaften im Fokus16
DiJaguar Health provides drug for expanded access to treat rare disease3
DiJaguar Health, Inc.: FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease107The two programs are being conducted under separate Single-Patient Investigational New Drug (sIND) applications in the United States SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Jaguar...
► Artikel lesen
26.09.Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY252Original-Research: Jaguar Health Inc - from First Berlin Equity Research GmbH 26.09.2025 / 12:17 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer...
► Artikel lesen
25.09.Jaguar Health erhält 250.000 US-Dollar FDA-Förderung für Studie zu Hunde-Diarrhö-Medikament7
25.09.Jaguar Health receives $250,000 FDA grant for canine diarrhea drug study3
25.09.Jaguar Health, Inc.: Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs216Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally SAN FRANCISCO...
► Artikel lesen
24.09.Jaguar Health, Inc.: Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition172Potential treatment for patients with breast cancer with metastasis to the brain with crofelemer would augment the significant responder analysis results for crofelemer in the prespecified subgroup...
► Artikel lesen
23.09.Jaguar Health, Inc.: Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts152SAN FRANCISCO, CA / ACCESS Newswire / September 23, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday...
► Artikel lesen
11.09.Jaguar Health, Inc. - 8-K, Current Report5
05.09.Jaguar Health, Inc.: Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts299Click here to register SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 5, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO,...
► Artikel lesen
21.08.Jaguar Health, Inc.: Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs318Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogsCompany strategy: In discussions with multiple potential...
► Artikel lesen
20.08.Jaguar Health gibt strategische Einblicke in die Medikamentenentwicklung8
19.08.Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders816Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to registerAs announced, initial proof-of-concept results from the ongoing...
► Artikel lesen
19.08.Jaguar Health to meet with FDA on crofelemer for rare pediatric disease4
19.08.Jaguar Health, Inc.: Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease134As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID...
► Artikel lesen
Weiter >>
118 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1